FGF2 and cancer: Concomitant inhibition of VEGF- and FGF2-induced EC proliferation and targeting only dividing ECs without affecting the survival of ECs are two properties rendering 6-ME as an attractive molecule for the development of a novel anti-angiogenic intervention in cancer treatment.